<div id="readability-page-1"><div> <p>By Josh Beckerman</p> <pre></pre> <p>   Shares of Eton Pharmaceuticals initially rose but pared their gains after the Food and Drug Administration approved Desmoda oral solution for management of central diabetes insipidus as antidiuretic replacement therapy. </p> <p>   Prior to a trading halt before the company's announcement, shares were at $17.69. The stock peaked at $19.98 Wednesday afternoon but was recently down 1.5% for the day at $18. </p> <p>   Eton expects a March 9 commercial launch for Desmoda, an oral liquid formulation of desmopressin. The company expects product peak sales of $30 million to $50 million annually. </p> <pre></pre> <p>   Write to Josh Beckerman at josh.beckerman@wsj.com </p> <pre></pre> <p>   (END) Dow Jones Newswires</p> <p>   February 25, 2026 15:29 ET (20:29 GMT)</p><p>Copyright (c) 2026 Dow Jones &amp; Company, Inc.</p></div></div>

<p>Eton Pharmaceuticals' shares rose initially after the FDA approved Desmoda for central diabetes insipidus management but later fell 1.5% to $18. The stock peaked at $19.98 following the announcement. Eton plans to launch Desmoda on March 9, anticipating annual peak sales of $30 million to $50 million.</p>

MorningStar

iShares Biotechnology ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Eton Pharmaceuticals

VanEck Biotech ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

Proshares Ultra Nasdaq Biotech

Eton Pharmaceuticals Rises After an FDA Approval But Pares Gains